Abstracts tagged "clinical research and scleroderma"

Abstract Number: 2890 • 2016 ACR/ARHP Annual Meeting
Feasibility of Same Day Adipose Tissue Harvest, Cell Processing and Subcutaneous Delivery of Adipose Derived Regenerative Cells into Fingers of Scleroderma Patients within a Randomized Double Blind Clinical Trial
Dinesh Khanna¹, Maureen D Mayes², Robert W. Simms³, Virginia D. Steen⁴, Steven Cohen⁵, Paul Caldron⁶, Richard Martin⁷, Suzanne Kafaja⁸, Ankoor Shah⁹, Shadi Shahouri¹⁰, Robert F. Spiera¹¹, John Ervin¹², Vivien Hsu¹³, Robyn T. Domsic¹⁴, Laura K. Hummers¹⁵, John Yocum¹⁶, Soumya Chatterjee¹⁷, Chris T. Derk¹⁸, John Varga¹⁹, Mark Adams²⁰, Eve M. Taylor²¹, Steven Kesten²¹ and Daniel E. Furst²², ¹University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ³Rheumatology, Boston University School of Medicine, Boston, MA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵FacesPlus, San Diego, CA, ⁶Arizona Arthritis and Rheumatology Associates, Phoenix, AZ, ⁷West Michigan Rheumatology, Grand Rapids, MI, ⁸Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Heartland Research Associates, Wichitas, KS, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Center for Pharmaceutical Research, Kansas City, MO, ¹³RWJ Medical School, New Brunswick, NJ, ¹⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Baptist Health Center for Clinical Research, Little Rock, AR, ¹⁷Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, ¹⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁹Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²⁰Central Kentucky Research, Lexington, KY, ²¹Cytori Therapeutics, Inc., San Diego, CA, ²²Arthritis Associates of Southern California, Los Angeles, CA
Background/Purpose: Current medical therapy to improve hand function has had very limited benefit in patients with systemic sclerosis (SSc). Cells present within a person’s own…
Abstract Number: 2916 • 2013 ACR/ARHP Annual Meeting
Anti-Fibrillarin Antibodies Are Associated With More Severe Gastrointestinal Involvement and Poorer Survival
Shervin Assassi¹, Marie Hudson², Maureen D. Mayes³, Jennifer Walker⁴, Murray Baron^5,6, Wendy Stevens⁷, Karen Patterson⁸, Tiffany Graham¹, Solene Tatibouet⁹, James Wick¹⁰, Matt Stephenson¹¹ and Marvin J. Fritzler¹¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³University of Texas Health Science Center at Houston, Houston, TX, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵McGill University, Montreal, QC, Canada, ⁶MCGill University, Montreal, QC, Canada, ⁷Rheumatology, St Vincent's Hospital, Melbourne, Australia, ⁸Institute of Medical and Veterinary Science, North Adelaide, Australia, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Department of medicine, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-fibrillarin (U3-RNP) antibodies (AFA) are a relatively specific biomarker for systemic sclerosis (SSc). Previous studies have indicated a higher prevalence of AFA among African…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].